Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi Sells 5,827 Shares of Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 5,827 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $27.31, for a total value of $159,135.37. Following the transaction, the chief financial officer now owns 141,846 shares in the company, valued at $3,873,814.26. This trade represents a 3.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Balaji Gandhi also recently made the following trade(s):

• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total value of $22,555.28.
• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total value of $85,018.95.

Phreesia Trading Down 0.2 %

Shares of Phreesia stock opened at $27.29 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The company has a fifty day simple moving average of $23.77 and a 200-day simple moving average of $22.94. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.16.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $106.33 million. During the same quarter in the previous year, the firm earned ($0.58) earnings per share. The business’s revenue was up 16.6% compared to the same quarter last year. As a group, equities analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Institutional Investors Weigh In On Phreesia

Several hedge funds have recently made changes to their positions in the business. International Assets Investment Management LLC raised its stake in Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after acquiring an additional 1,395 shares during the last quarter. Lombard Odier Asset Management USA Corp acquired a new position in shares of Phreesia in the second quarter valued at approximately $202,000. Point72 DIFC Ltd purchased a new stake in shares of Phreesia during the second quarter worth approximately $209,000. XTX Topco Ltd acquired a new stake in shares of Phreesia during the third quarter worth $247,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Phreesia during the second quarter worth $301,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Analyst Ratings Changes

PHR has been the topic of several research reports. Robert W. Baird reduced their price target on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. JMP Securities reissued a “market outperform” rating and issued a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Truist Financial upped their price objective on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Citigroup lifted their target price on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. Finally, Needham & Company LLC reissued a “buy” rating and set a $29.00 target price on shares of Phreesia in a research note on Friday, January 10th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $31.00.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.